POSTERS A: Risk Factors| Volume 138, SUPPLEMENT 1, S95, October 2020

Evaluation of FISH of ER-positive breast cancer with low-HER2 expression could improve their survival

      Background: Several prognostic and predictive biomarkers for decision-making regarding neo-adjuvant (NAC) and adjuvant treatment in estrogen receptor (ER)-positive breast cancer patients have been developed. However, their ability to predict patient prognosis and treatment outcomes is poor. Hence, validated markers for predicting prognosis and treatment outcomes need to be developed. Expression of human epidermal growth factor receptor 2 (HER2) is evaluated by immunohistochemistry (IHC), and its gene amplification by Fluorescence in situ Hybridization (FISH) is not always examined. In our hospital, HER2 FISH has been assessed in almost all patients including those with HER2 status 0 and 1 (i.e., low-HER2 expression). Moreover, anti HER2 chemotherapy is administered if the patient’s status is low-HER2 FISH-positive. In this report, we retrospectively investigated the ratio and characteristics of low-HER2 FISH-positive patients and compared their recurrence-free survival (RFS) with that of luminal A FISH-negative patients to examine whether evaluation of HER2 FISH in luminal A breast cancer could improve survival.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect